Lux Capital, a New York venture investor, put together a $350 million fourth fund, cash that will help bankroll startups in energy, technology and biotech. The firm, which also has an outpost in Menlo Park, CA, boasts a life sciences portfolio that includes Cerulean Pharma ($CERU), Kala Pharmaceuticals, Visterra and Genocea Biosciences ($GNCA). More